Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ALK |
| Variant | D1203N |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | ALK D1203N lies within the protein kinase domain of the Alk protein (UniProt.org). D1203N has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK fusions (PMID: 35123209, PMID: 27432227, PMID: 28434515), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Nov 2025). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
ALK mutant ALK D1203N |
| Transcript | NM_004304.5 |
| gDNA | chr2:g.29220744C>T |
| cDNA | c.3607G>A |
| Protein | p.D1203N |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004304 | chr2:g.29220744C>T | c.3607G>A | p.D1203N | RefSeq | GRCh38/hg38 |
| NM_004304.4 | chr2:g.29220744C>T | c.3607G>A | p.D1203N | RefSeq | GRCh38/hg38 |
| NM_004304.5 | chr2:g.29220744C>T | c.3607G>A | p.D1203N | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK D1203N | Advanced Solid Tumor | decreased response | TPX-0131 | Preclinical - Biochemical | Actionable | In a preclinical study, ALK D1203N demonstrated reduced sensitivity to TPX-0131 in an in vitro kinase assay (PMID: 34158340). | 34158340 |